InterVenn Biosciences
PrivateLast Round
Series C
Aug 2, 2021
Total Funding Raised
$244.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
InterVenn Biosciences operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series C round in August 2021.
InterVenn Biosciences is a biotechnology company that develops an AI-powered platform for glycoproteomic analysis to enhance early cancer detection and precision medicine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InterVenn Biosciences Comparables
Compare InterVenn Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PrognomiQ | 82% | |
| AOA Dx | 79% | |
| Harbinger Health | 78% |
For institutional investors. Book with your work email.
InterVenn Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 2, 2021 | ||||
| Series B | Nov 16, 2020 | ||||
| Series A | Dec 12, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
InterVenn Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Xeraya Capital | Series B, Series C |
| Ojjeh Family | Series B |
| Highside Capital Management | Series C |
| Prado SV | Series A |
| SoftBank Group | Series C |
| Genoa Ventures | Series B, Series C, Series A |
| Irving Investors | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 5, 2026
Product awarded 'Clinical Diagnostics Solution of the Year'.
- Aug 21, 2026
Monthly visitors increased 64% MoM, reaching 2.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardNov 5, 2026
BioTech Breakthrough awards InterVenn's GlycoKnow(R) Ovarian "Clinical Diagnostics Solution of the Year" in its sixth annual BioTech Breakthrough Awards program in California on Nov 5th '26.
- attends_eventNov 5, 2026
InterVenn's GlycoKnow(R) Ovarian receives Clinical Diagnostics Solution of the Year at the sixth annual BioTech Breakthrough Awards in California on Nov 5th '26.
For institutional investors. Book with your work email.
InterVenn Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about InterVenn Biosciences's valuation, stock price, and market status.
Is InterVenn Biosciences a public or private company?
InterVenn Biosciences is a private company.
What is the current stock price of InterVenn Biosciences?
InterVenn Biosciences is a private company, so its shares have no public market price. Caplight tracks InterVenn Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is InterVenn Biosciences worth (valuation)?
Valuation information for InterVenn Biosciences is not publicly available.
Can I buy InterVenn Biosciences stock?
InterVenn Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was InterVenn Biosciences's last funding round?
InterVenn Biosciences's most recent funding round was Series C on August 2, 2021.
Who are the main investors in InterVenn Biosciences?
Key investors in InterVenn Biosciences include SoftBank Group, Genoa Ventures, Anzu Partners, HIGHSIDE Global.
Will InterVenn Biosciences IPO soon?
No public IPO plans have been announced for InterVenn Biosciences.
How can I track InterVenn Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in InterVenn Biosciences's shares on secondary markets.